The main questions that need to be answered are whether the only difference between these two diseases is the time of their onset and whether the only difference between them with respect to fetal morbidity and mortality is prematurity
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim of this study is to determine whether maternal serum ADAMTS-12 levels differ among early-onset (<34th week) severe preeclampsia (EOS-PE), late-onset (≥ 34th week) severe preeclampsia (LOS-PE), and uncomplicated pregnancies.
📊
Key Findings & Data:In this case-control study, maternal serum samples obtained from 22 pregnant patients with EOS-PE, 25 pregnant patients with LOS-PE, and 35 healthy patients with uncomplicated pregnancies (control group).
💡
Conclusion & Impact:The main questions that need to be answered are whether the only difference between these two diseases is the time of their onset and whether the only difference between them with respect to fetal morbidity and mortality is prematurity
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aim of this study is to determine whether maternal serum ADAMTS-12 levels differ among early-onset (<34th week) severe preeclampsia (EOS-PE), late-onset (≥ 34th week) severe preeclampsia (LOS-PE), and uncomplicated pregnancies. In this case-control study, maternal serum samples obtained from 22 pregnant patients with EOS-PE, 25 pregnant patients with LOS-PE, and 35 healthy patients with uncomplicated pregnancies (control group). The distinctly higher rate of negative perinatal outcomes in both EOS-PE and LOS-PE patients were recorded. There were no significant differences among the ADAMTS-12 levels of the groups. The main questions that need to be answered are whether the only difference between these two diseases is the time of their onset and whether the only difference between them with respect to fetal morbidity and mortality is prematurity
🔖
Cite This Article
KIRBAŞ, A., DAĞLAR, K., TİMUR, H., YILMAZ, Z., GENCOSMANOGLU, G., DANIŞMAN, N. (2016). Circulating ADAMTS-12 levels in early- and late-onset severe preeclampsia. Medicine Science, Cilt: 5 - Sayı: 3, 785–789. https://ajindex.com/articles/277751
Harmon AC, Cornelius DC, Amaral LM, Faulkner JL, Cunningham MW Jr, Wallace K, LaMarca B. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond). 2016;130(6):409-19
Kirbas O, Biberoglu EH, Kirbas A, Daglar HK, Kurmus O, Uygur D, Danisman N. P-wave duration changes and dispersion in preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2014;183:141-5
Valensise H, Vasapollo B, Gagliardi G, Novelli GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008;52(5):873-80 4. Kirbas A, Ersoy AO, Daglar K, Dikici T, Biberoglu EH, Kirbas O, Danisman N. Prediction of preeclampsia by first trimester combined test and simple complete blood count parameters. J Clin Diagn Res. 2015;9(11):QC20-3
Redman CW, Sargent IL, Staff AC. IFPA Senior Award Lecture: making sense of pre-eclampsia - two placental causes of preeclampsia? Placenta. 2014:35(Suppl):S20-5
Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia Curr Drug Targets. 2013;14(3):325-34
Wei J, Richbourgh B, Jia T, Liu C. ADAMTS-12: a multifaced metalloproteinase in arthritis and inflammation. Mediators Inflamm. 2014;2014:649718
Beristain AG, Zhu H, Leung PC. Regulated expression of ADAMTS- 12 in human trophoblastic cells: a role for ADAMTS-12 in epithelial cell invasion? PLoS One. 2011;6(4):e18473
Eda Gökdemir İ, Özdeğirmenci Ö, Elmas B, Sarikaya E, Tokmak A, Kazanci FH, Gök S, Erkaya S, Demircan K. Evaluation of ADAMTS12, ADAMTS16, ADAMTS18 and IL-33 serum levels in pre-eclampsia. J Matern Fetal Neonatal Med. 2015;18:1-6
Barfield WD. Committee on fetus and newborn. publications committee, society for maternal-fetal medicine, standard terminology for fetal, infant, and perinatal deaths. Pediatrics. 2011;128(1):177-81
Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011;205(3):191-8
Palei AC, Granger JP, Tanus-Santos JE. Matrix metalloproteinases as drug targets in preeclampsia Curr Drug Targets. 2013;14(3):325-3